Browse PPP2R2D

Summary
SymbolPPP2R2D
Nameprotein phosphatase 2, regulatory subunit B, delta
Aliases MDS026; PP2A subunit B isoform delta; protein phosphatase 2, regulatory subunit B, delta isoform; PP2A subun ......
Chromosomal Location10q26.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm
Domain -
Function

B regulatory subunit of protein phosphatase 2A (PP2A) that plays a key role in cell cycle by controlling mitosis entry and exit. The activity of PP2A complexes containing PPP2R2D (PR55-delta) fluctuate during the cell cycle: the activity is high in interphase and low in mitosis. During mitosis, activity of PP2A is inhibited via interaction with phosphorylated ENSA and ARPP19 inhibitors. Within the PP2A complexes, the B regulatory subunits modulate substrate selectivity and catalytic activity, and also may direct the localization of the catalytic enzyme to a particular subcellular compartment (By similarity).

> Gene Ontology
 
Biological Process GO:0006470 protein dephosphorylation
GO:0007067 mitotic nuclear division
GO:0010458 exit from mitosis
GO:0010921 regulation of phosphatase activity
GO:0016311 dephosphorylation
GO:0034047 regulation of protein phosphatase type 2A activity
GO:0035303 regulation of dephosphorylation
GO:0035304 regulation of protein dephosphorylation
GO:0043666 regulation of phosphoprotein phosphatase activity
GO:0044770 cell cycle phase transition
GO:0044772 mitotic cell cycle phase transition
GO:0070262 peptidyl-serine dephosphorylation
Molecular Function GO:0004721 phosphoprotein phosphatase activity
GO:0004722 protein serine/threonine phosphatase activity
GO:0008601 protein phosphatase type 2A regulator activity
GO:0016791 phosphatase activity
GO:0019208 phosphatase regulator activity
GO:0019888 protein phosphatase regulator activity
GO:0042578 phosphoric ester hydrolase activity
Cellular Component GO:0000159 protein phosphatase type 2A complex
GO:0008287 protein serine/threonine phosphatase complex
GO:1903293 phosphatase complex
> KEGG and Reactome Pathway
 
KEGG hsa03015 mRNA surveillance pathway
hsa04071 Sphingolipid signaling pathway
hsa04151 PI3K-Akt signaling pathway
hsa04152 AMPK signaling pathway
hsa04261 Adrenergic signaling in cardiomyocytes
hsa04390 Hippo signaling pathway
hsa04530 Tight junction
hsa04728 Dopaminergic synapse
Reactome R-HSA-1640170: Cell Cycle
R-HSA-69278: Cell Cycle, Mitotic
R-HSA-68886: M Phase
R-HSA-2465910: MASTL Facilitates Mitotic Progression
R-HSA-68875: Mitotic Prophase
Summary
SymbolPPP2R2D
Nameprotein phosphatase 2, regulatory subunit B, delta
Aliases MDS026; PP2A subunit B isoform delta; protein phosphatase 2, regulatory subunit B, delta isoform; PP2A subun ......
Chromosomal Location10q26.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between PPP2R2D and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between PPP2R2D and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
24476824MelanomaInhibit immunity (T cell function)In tumours, Ppp2r2d knockdown inhibited T-cell apoptosis and enhanced T-cell proliferation as well as cytokine production.
Summary
SymbolPPP2R2D
Nameprotein phosphatase 2, regulatory subunit B, delta
Aliases MDS026; PP2A subunit B isoform delta; protein phosphatase 2, regulatory subunit B, delta isoform; PP2A subun ......
Chromosomal Location10q26.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of PPP2R2D in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen Total # shRNA with >= 4-fold: 5 Resistant to T-cell proliferation
Summary
SymbolPPP2R2D
Nameprotein phosphatase 2, regulatory subunit B, delta
Aliases MDS026; PP2A subunit B isoform delta; protein phosphatase 2, regulatory subunit B, delta isoform; PP2A subun ......
Chromosomal Location10q26.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of PPP2R2D in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.0160.925
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.1250.905
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.0610.935
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.0540.837
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.1160.947
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.020.993
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.0310.919
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.0430.972
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.0220.987
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.2360.847
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.0760.966
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0520.46
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of PPP2R2D in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277302.7-2.71
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 01407.1-7.11
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275901.7-1.71
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 382703.7-3.70.415
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221307.7-7.70.371
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolPPP2R2D
Nameprotein phosphatase 2, regulatory subunit B, delta
Aliases MDS026; PP2A subunit B isoform delta; protein phosphatase 2, regulatory subunit B, delta isoform; PP2A subun ......
Chromosomal Location10q26.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of PPP2R2D. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolPPP2R2D
Nameprotein phosphatase 2, regulatory subunit B, delta
Aliases MDS026; PP2A subunit B isoform delta; protein phosphatase 2, regulatory subunit B, delta isoform; PP2A subun ......
Chromosomal Location10q26.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of PPP2R2D. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by PPP2R2D.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolPPP2R2D
Nameprotein phosphatase 2, regulatory subunit B, delta
Aliases MDS026; PP2A subunit B isoform delta; protein phosphatase 2, regulatory subunit B, delta isoform; PP2A subun ......
Chromosomal Location10q26.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of PPP2R2D. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolPPP2R2D
Nameprotein phosphatase 2, regulatory subunit B, delta
Aliases MDS026; PP2A subunit B isoform delta; protein phosphatase 2, regulatory subunit B, delta isoform; PP2A subun ......
Chromosomal Location10q26.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of PPP2R2D expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolPPP2R2D
Nameprotein phosphatase 2, regulatory subunit B, delta
Aliases MDS026; PP2A subunit B isoform delta; protein phosphatase 2, regulatory subunit B, delta isoform; PP2A subun ......
Chromosomal Location10q26.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between PPP2R2D and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolPPP2R2D
Nameprotein phosphatase 2, regulatory subunit B, delta
Aliases MDS026; PP2A subunit B isoform delta; protein phosphatase 2, regulatory subunit B, delta isoform; PP2A subun ......
Chromosomal Location10q26.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting PPP2R2D collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.